Rezolute Seeks FDA Path Forward After Mixed Phase 3 Results for Congenital Hyperinsulinism Drug

Event summary

  • Rezolute's Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism missed primary endpoint due to behavioral study effects, though secondary endpoints showed clinically significant improvements.
  • FDA acknowledged trial challenges but reiterated need for robust efficacy evidence, encouraging Rezolute to submit comprehensive data for independent review.
  • Preliminary open-label extension data suggests continued glycemic improvements, potentially supporting future marketing applications.
  • Rezolute expects to provide an update on the program in the second half of 2026.

The big picture

Rezolute's challenge reflects broader difficulties in rare disease trials where behavioral factors can confound traditional endpoints. The FDA's willingness to engage suggests potential flexibility in evaluating therapies for ultra-orphan conditions, though the path to approval remains uncertain. The outcome will test whether clinically meaningful improvements can overcome statistical hurdles in regulatory decisions.

What we're watching

Regulatory Strategy
Whether FDA's independent review of sunRIZE data will overcome the lack of statistical significance in primary endpoints.
Clinical Efficacy
The pace at which open-label extension data may strengthen the case for ersodetug's approval.
Market Timing
How Rezolute's ability to secure a marketing application will impact its competitive positioning in congenital hyperinsulinism.